Biocept Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BIOC Nasdaq 2834 https://biocept.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biocept Inc

Biocept Awarded Canadian Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells, from a Biological Fluid Sample such as Blood or Cerebrospinal Fluid - Jun 30th, 2020 12:05 pm
Biocept’s Covid-19 Testing Capacity Puts It at the Head of the Pack - Jun 27th, 2020 2:04 am
Biocept Enters Into Agreement with Reference-based Pricing Network Medical Cost Containment Professionals, LLC to Process Out-of-Network Claims - Jun 24th, 2020 12:05 pm
Biocept Announces the Availability of 10,000 Specimen Collection Kits for RT-PCR COVID-19 Testing - Jun 22nd, 2020 12:05 pm
Biocept to Relocate Corporate Offices and CLIA-Certified Laboratory to New San Diego Location - Jun 5th, 2020 12:05 pm
Data Affirming Biocept's Target Selector™ Platform Identifies Cancer Mutations in Cerebrospinal Fluid Presented at ASCO 2020 Virtual Scientific Program - May 29th, 2020 12:30 pm
Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020 - May 20th, 2020 12:05 pm
Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories - May 14th, 2020 12:05 pm
Biocept Reports First Quarter 2020 Financial Results - May 13th, 2020 8:05 pm
Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference Call on May 13, 2020 - Apr 29th, 2020 12:05 pm
Biocept Announces CE-IVD Mark and Availability of its Target Selector™ EGFR Molecular Assay Kit in Europe - Apr 28th, 2020 12:05 pm
Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector™ Technology Validated for Use in Both Tissue and Blood Samples - Apr 20th, 2020 12:05 pm
Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market - Apr 14th, 2020 1:00 pm
Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics - Apr 13th, 2020 1:54 pm
Biocept to Begin COVID-19 Testing - Apr 9th, 2020 11:17 pm
Brazil Patent Granted for Biocept's Target Selector™ Oncogene Mutation Enrichment and Detection Platform - Apr 9th, 2020 12:05 pm
Australia Patent Issued for Primer-Switch Mutation Detection and Amplification Platform - Apr 2nd, 2020 12:05 pm
For Penny Investors, Biocept Stock Makes a Good Speculative Play - Apr 1st, 2020 11:53 pm
US$1.00: That's What Analysts Think Biocept, Inc. (NASDAQ:BIOC) Is Worth After Its Latest Results - Mar 28th, 2020 12:23 pm
Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician Association - Mar 26th, 2020 12:05 pm